86 Citations (Scopus)

Abstract

Background: Circulating soluble interleukin-2 receptors (sIL-2Rs) and soluble interleukin-6 receptors (sIL-6Rs) are stable immune measures. Elevated plasma sIL-2R levels are present in patients with schizophrenia, major depression, and bipolar mania, but not with minor psychiatric disorders. The increased plasma sIL-2R levels are state-dependent in bipolar mania. However, altered production of plasma sIL-6R and the effects of clinical characteristics on plasma sIL-6R and sIL-2R levels in bipolar disorder remains uncertain. Methods: Plasma sIL-2R and sIL-6R levels were measured in 31 Taiwanese bipolar manic (DSM-IV) patients with Young Mania Rating Scale (YMRS) scores of ≥26 as well as during the subsequent remission (YMRS≤ 12), and equal numbers of age- and gender-matched healthy controls. The relationships of clinical variables such as age, age of onset, smoking, medication status, coexisting psychotic features, number of prior episodes, duration of illness, presence of depression before or following the manic episode, and manic severity to plasma sIL-2R and sIL-6R levels in acute mania along with remission were examined. Results: Plasma sIL-2R but not sIL-6R levels were significantly higher in acute mania than in subsequent remission (P <0.05) and controls (P <0.0005). In acute mania, the plasma sIL-2R levels were significantly correlated to YMRS scores (r = 0.34, P <0.05). The remaining clinical variables had no effect on plasma sIL-2R and sIL-6R levels in acute mania or remission. There was a significantly positive relationship between the reduction of plasma sIL-2R levels from the acute to follow-up measurements (ΔsIL-2R) and symptomatic improvement of acute mania (ΔYMRS) (r = 0.61, P <0.001). Limitations: Our sample included medicated and unmedicated patients in acute mania. The psychotropic medication may have divergent effects on the plasma sIL-2R levels in acute mania and subsequent remission. Conclusions: Elevation of plasma sIL-2R but not sIL-6R levels in bipolar mania supports the idea that the immunomodulatory mechanism may vary in different psychotic disorders. In contrast to being a trait marker in schizophrenia and depressive disorder, plasma sIL-2R levels may be considered a biological indicator of manic severity in a group of bipolar affective patients.

Original languageEnglish
Pages (from-to)185-193
Number of pages9
JournalJournal of Affective Disorders
Volume64
Issue number2-3
DOIs
Publication statusPublished - 2001

Fingerprint

Interleukin-2 Receptors
Bipolar Disorder
Schizophrenia
Interleukin-6 Receptors
Depressive Disorder
Age of Onset
Diagnostic and Statistical Manual of Mental Disorders
Psychotic Disorders

Keywords

  • Bipolar disorder in Taiwan
  • Severity of mania
  • Soluble interleukin-2 receptors (sIL-2R)
  • Soluble interleukin-6 receptor (sIL-6R)

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. / Tsai, Shang Ying M; Yang, Yi Yuan; Kuo, Chian Jue; Chen, Chiao Chicy; Leu, Sy Jye C.

In: Journal of Affective Disorders, Vol. 64, No. 2-3, 2001, p. 185-193.

Research output: Contribution to journalArticle

@article{a1da6f23f6d245b3829d45859b5e255d,
title = "Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania",
abstract = "Background: Circulating soluble interleukin-2 receptors (sIL-2Rs) and soluble interleukin-6 receptors (sIL-6Rs) are stable immune measures. Elevated plasma sIL-2R levels are present in patients with schizophrenia, major depression, and bipolar mania, but not with minor psychiatric disorders. The increased plasma sIL-2R levels are state-dependent in bipolar mania. However, altered production of plasma sIL-6R and the effects of clinical characteristics on plasma sIL-6R and sIL-2R levels in bipolar disorder remains uncertain. Methods: Plasma sIL-2R and sIL-6R levels were measured in 31 Taiwanese bipolar manic (DSM-IV) patients with Young Mania Rating Scale (YMRS) scores of ≥26 as well as during the subsequent remission (YMRS≤ 12), and equal numbers of age- and gender-matched healthy controls. The relationships of clinical variables such as age, age of onset, smoking, medication status, coexisting psychotic features, number of prior episodes, duration of illness, presence of depression before or following the manic episode, and manic severity to plasma sIL-2R and sIL-6R levels in acute mania along with remission were examined. Results: Plasma sIL-2R but not sIL-6R levels were significantly higher in acute mania than in subsequent remission (P <0.05) and controls (P <0.0005). In acute mania, the plasma sIL-2R levels were significantly correlated to YMRS scores (r = 0.34, P <0.05). The remaining clinical variables had no effect on plasma sIL-2R and sIL-6R levels in acute mania or remission. There was a significantly positive relationship between the reduction of plasma sIL-2R levels from the acute to follow-up measurements (ΔsIL-2R) and symptomatic improvement of acute mania (ΔYMRS) (r = 0.61, P <0.001). Limitations: Our sample included medicated and unmedicated patients in acute mania. The psychotropic medication may have divergent effects on the plasma sIL-2R levels in acute mania and subsequent remission. Conclusions: Elevation of plasma sIL-2R but not sIL-6R levels in bipolar mania supports the idea that the immunomodulatory mechanism may vary in different psychotic disorders. In contrast to being a trait marker in schizophrenia and depressive disorder, plasma sIL-2R levels may be considered a biological indicator of manic severity in a group of bipolar affective patients.",
keywords = "Bipolar disorder in Taiwan, Severity of mania, Soluble interleukin-2 receptors (sIL-2R), Soluble interleukin-6 receptor (sIL-6R)",
author = "Tsai, {Shang Ying M} and Yang, {Yi Yuan} and Kuo, {Chian Jue} and Chen, {Chiao Chicy} and Leu, {Sy Jye C}",
year = "2001",
doi = "10.1016/S0165-0327(00)00252-4",
language = "English",
volume = "64",
pages = "185--193",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania

AU - Tsai, Shang Ying M

AU - Yang, Yi Yuan

AU - Kuo, Chian Jue

AU - Chen, Chiao Chicy

AU - Leu, Sy Jye C

PY - 2001

Y1 - 2001

N2 - Background: Circulating soluble interleukin-2 receptors (sIL-2Rs) and soluble interleukin-6 receptors (sIL-6Rs) are stable immune measures. Elevated plasma sIL-2R levels are present in patients with schizophrenia, major depression, and bipolar mania, but not with minor psychiatric disorders. The increased plasma sIL-2R levels are state-dependent in bipolar mania. However, altered production of plasma sIL-6R and the effects of clinical characteristics on plasma sIL-6R and sIL-2R levels in bipolar disorder remains uncertain. Methods: Plasma sIL-2R and sIL-6R levels were measured in 31 Taiwanese bipolar manic (DSM-IV) patients with Young Mania Rating Scale (YMRS) scores of ≥26 as well as during the subsequent remission (YMRS≤ 12), and equal numbers of age- and gender-matched healthy controls. The relationships of clinical variables such as age, age of onset, smoking, medication status, coexisting psychotic features, number of prior episodes, duration of illness, presence of depression before or following the manic episode, and manic severity to plasma sIL-2R and sIL-6R levels in acute mania along with remission were examined. Results: Plasma sIL-2R but not sIL-6R levels were significantly higher in acute mania than in subsequent remission (P <0.05) and controls (P <0.0005). In acute mania, the plasma sIL-2R levels were significantly correlated to YMRS scores (r = 0.34, P <0.05). The remaining clinical variables had no effect on plasma sIL-2R and sIL-6R levels in acute mania or remission. There was a significantly positive relationship between the reduction of plasma sIL-2R levels from the acute to follow-up measurements (ΔsIL-2R) and symptomatic improvement of acute mania (ΔYMRS) (r = 0.61, P <0.001). Limitations: Our sample included medicated and unmedicated patients in acute mania. The psychotropic medication may have divergent effects on the plasma sIL-2R levels in acute mania and subsequent remission. Conclusions: Elevation of plasma sIL-2R but not sIL-6R levels in bipolar mania supports the idea that the immunomodulatory mechanism may vary in different psychotic disorders. In contrast to being a trait marker in schizophrenia and depressive disorder, plasma sIL-2R levels may be considered a biological indicator of manic severity in a group of bipolar affective patients.

AB - Background: Circulating soluble interleukin-2 receptors (sIL-2Rs) and soluble interleukin-6 receptors (sIL-6Rs) are stable immune measures. Elevated plasma sIL-2R levels are present in patients with schizophrenia, major depression, and bipolar mania, but not with minor psychiatric disorders. The increased plasma sIL-2R levels are state-dependent in bipolar mania. However, altered production of plasma sIL-6R and the effects of clinical characteristics on plasma sIL-6R and sIL-2R levels in bipolar disorder remains uncertain. Methods: Plasma sIL-2R and sIL-6R levels were measured in 31 Taiwanese bipolar manic (DSM-IV) patients with Young Mania Rating Scale (YMRS) scores of ≥26 as well as during the subsequent remission (YMRS≤ 12), and equal numbers of age- and gender-matched healthy controls. The relationships of clinical variables such as age, age of onset, smoking, medication status, coexisting psychotic features, number of prior episodes, duration of illness, presence of depression before or following the manic episode, and manic severity to plasma sIL-2R and sIL-6R levels in acute mania along with remission were examined. Results: Plasma sIL-2R but not sIL-6R levels were significantly higher in acute mania than in subsequent remission (P <0.05) and controls (P <0.0005). In acute mania, the plasma sIL-2R levels were significantly correlated to YMRS scores (r = 0.34, P <0.05). The remaining clinical variables had no effect on plasma sIL-2R and sIL-6R levels in acute mania or remission. There was a significantly positive relationship between the reduction of plasma sIL-2R levels from the acute to follow-up measurements (ΔsIL-2R) and symptomatic improvement of acute mania (ΔYMRS) (r = 0.61, P <0.001). Limitations: Our sample included medicated and unmedicated patients in acute mania. The psychotropic medication may have divergent effects on the plasma sIL-2R levels in acute mania and subsequent remission. Conclusions: Elevation of plasma sIL-2R but not sIL-6R levels in bipolar mania supports the idea that the immunomodulatory mechanism may vary in different psychotic disorders. In contrast to being a trait marker in schizophrenia and depressive disorder, plasma sIL-2R levels may be considered a biological indicator of manic severity in a group of bipolar affective patients.

KW - Bipolar disorder in Taiwan

KW - Severity of mania

KW - Soluble interleukin-2 receptors (sIL-2R)

KW - Soluble interleukin-6 receptor (sIL-6R)

UR - http://www.scopus.com/inward/record.url?scp=0035062306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035062306&partnerID=8YFLogxK

U2 - 10.1016/S0165-0327(00)00252-4

DO - 10.1016/S0165-0327(00)00252-4

M3 - Article

C2 - 11313085

AN - SCOPUS:0035062306

VL - 64

SP - 185

EP - 193

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 2-3

ER -